DiaMedica Therapeutics Inc. (DMAC) Cash and securities
- Total cash · latest quarter (USD): Value $43.50M; Formula and calculation Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30..
- Cash per share · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30..
Cash and securities
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total cash · latest quarter (USD) | $43.50M | Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30. $5.13M + $38.38M ≈ $43.50M |
| Cash per share · latest quarter | (m) | Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash and equivalents | 5.13M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 38.38M USD | Marketable Securities, Current |
| Cash and current securities | 43.50M USD | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total cash | Cash per share | Cash and equivalents (USD) | Short-term securities (USD) | Quarter-end shares (shares) |
|---|---|---|---|---|---|
| 2026-06-30 | $43.50M | (m) | $5.13M | $38.38M | (m) |
| 2026-03-31 | $51.33M | (m) | $4.87M | $46.46M | (m) |
| 2025-12-31 | $59.89M | (m) | $15.65M | $44.24M | (m) |
| 2025-09-30 | $55.32M | (m) | $3.33M | $51.99M | (m) |
| 2025-06-30 | $30.04M | (m) | $4.11M | $25.93M | (m) |
| 2025-03-31 | $36.32M | (m) | $2.59M | $33.73M | (m) |
| 2024-12-31 | $44.15M | (m) | $3.02M | $41.12M | (m) |
| 2024-09-30 | $50.20M | (m) | $4.13M | $46.06M | (m) |
| 2024-06-30 | $54.05M | (m) | $14.07M | $39.99M | (m) |
| 2024-03-31 | $46.52M | (m) | $2.10M | $44.42M | (m) |
| 2023-12-31 | $52.90M | (m) | $4.54M | $48.35M | (m) |
| 2023-09-30 | $46.47M | (m) | $2.23M | $44.23M | (m) |
| 2023-06-30 | $40.37M | (m) | $5.84M | $34.53M | (m) |
| 2023-03-31 | $28.66M | (m) | $2.15M | $26.51M | (m) |
| 2022-12-31 | $33.50M | (m) | $4.73M | $28.77M | (m) |
| 2022-09-30 | $36.08M | (m) | $2.77M | $33.31M | (m) |
| 2022-06-30 | $38.44M | (m) | $3.06M | $35.38M | (m) |
| 2022-03-31 | $41.05M | (m) | $3.03M | $38.02M | (m) |
| 2021-12-31 | $45.11M | (m) | $4.71M | $40.41M | (m) |
| 2021-09-30 | $48.10M | (m) | $16.22M | $31.88M | (m) |
| 2021-06-30 | $21.30M | (m) | $2.23M | $19.07M | (m) |
| 2021-03-31 | $23.40M | (m) | $3.33M | $20.07M | (m) |
| 2020-12-31 | $27.51M | (m) | $7.41M | $20.10M | (m) |
| 2020-09-30 | $30.62M | (m) | $9.80M | $20.83M | (m) |
| 2020-06-30 | $11.80M | (m) | $4.96M | $6.84M | (m) |
| 2020-03-31 | $12.65M | (m) | $3.30M | $9.35M | (m) |
| 2019-12-31 | $7.88M | (m) | $3.88M | $4.00M | (m) |
| 2019-09-30 | $9.74M | (m) | $4.74M | $5.00M | (m) |
| 2019-06-30 | $10.97M | (m) | $2.97M | $7.99M | (m) |
| 2019-03-31 | $13.72M | (m) | $2.76M | $10.96M | (m) |
| 2018-12-31 | (m) | (m) | $16.82M | (m) | (m) |
| 2018-09-30 | (m) | (m) | $3.90M | (m) | (m) |
| 2018-06-30 | (m) | (m) | $5.73M | (m) | (m) |
| 2018-03-31 | (m) | (m) | $6.71M | (m) | (m) |
| 2017-12-31 | (m) | (m) | $1.35M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |